723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning

• Lawrence G Lum,
• Martin Gutierrez,
• Sunil Patel,
• Michele Donato,
• Jee Hyun Park,
• Tania Felizardo,
• Daniel H Fowler,
• Morgan Finlay,
• Ronit Reich-Slotky,
• Research Nurse Coordinator

Affiliations

Lawrence G Lum

2University of Virginia, Charlottesville, VA, USA

Martin Gutierrez

5Hackensack University Medical Center, Hackensack, NJ, USA

Sunil Patel

1Hackensack Meridian Health, Edison, NJ, USA

Michele Donato

Stanford Institute for Immunity Transplantation and Infection, Stanford, California, USA

Jee Hyun Park

1Rapa Therapeutics, Rockville, MD, USA

Tania Felizardo

1Rapa Therapeutics, Rockville, MD, USA

Daniel H Fowler

1Rapa Therapeutics, Rockville, MD, USA

Morgan Finlay

1Hackensack Meridian Health, Hackensack, NJ, USA

Ronit Reich-Slotky

1Hackensack Meridian Health, Edison, NJ, USA

Research Nurse Coordinator

1Hackensack Meridian Health, Edison, NJ, USA